In addition, the drugs which target ferroptosis have shown to be capable of invasion inhibition in endometrial cancer, as in the case of juglone, which promoted HMOX1 expression, thereby inhibiting the migration of endometrial cancer (Yuan Y. et al., 2021) and of simvastatin which inhibited metastasis through the modulation of the MAPK and AKT/mTOR pathways (Schointuch et al., 2014). Here, HMOX1 is linked to endometrial cancer.